Scholars Central

Research articlePublished 2015

A Prospective Randomised Study of Postoperative Prophylactic Application of Sildenafil After Pediatric Cardiac Surgery

Authors: Anna Hofer, Martina Heschl, Clemens Kern, Eva Grohmann, Eva Sames-Dolzer, Hans Gombotz, Jens Meier

Clinical and Experimental Cardiology

Volume 6 · Issue 8 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Postoperative aggravation of pulmonary hypertension after pediatric cardiac surgery due to temporary endothelial dysfunction may lead to sudden pulmonary arterial pressure rise with compromise of right ventricular function. Though treatment with inhaled nitric oxid (NO) has been successful, rebound pulmonary hypertension has been observed after NO withdrawal due to supression of endogenous NO sythase. Sildenafil has been shown to prevent this reaction and is widely used after pediatric cardiac surgery. The aim of our study was to evaluate the effectively of postoperative administration of oral sildenafil (1 mg/kg/day) in preventing postoperative pulmonary hypertensive crises. 21 patients after repair of complete atrioventricular canal (n=10) or ventricular septal defect (n=11) were randomly assigned to the study group or control group. The study group received sildenafil after surgery via nasogastric tube every eight hours for 48 hours, the control group received placebo. The primary outcome parameter was the number of pulmonary hypertensive events (spontaneous pulmonary arterial pressure rise to or above systemic arterial pressure). Secondary outcome parameters were: need for inotropic drugs, fluid balance, urinary output, days on the ventilator or in the intensive care unit (ICU). There was no difference in the number of pulmonary hypertensive events between both groups: median (IQR); 2 (0-6,5) sildenafil, 1 (0-2) placebo, p=0,67. Neither inotrope score, time on the ventilator, ICU length of stay, nor fluid balance differed significantly. Urinary output was significantly lower in the sildenafil group.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical and Experimental Cardiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical and Experimental Cardiology
  • SubjectCardiology
  • BylineArticles whose byline prints “Anna Hofer”
  • BylineArticles whose byline prints “Martina Heschl”
  • BylineArticles whose byline prints “Clemens Kern”
  • BylineArticles whose byline prints “Eva Grohmann”
  • BylineArticles whose byline prints “Eva Sames-Dolzer”
  • BylineArticles whose byline prints “Hans Gombotz”
  • BylineArticles whose byline prints “Jens Meier”